SCHEMBL5272290

SCHEMBL5272290

N#CCCCOc1ccccc1-c1coc2cc(O)c(Cl)cc2c1=O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 3/20 0.43
▸ KDM4E B2RXH2 2/20 0.43
▸ USP2 O75604 2/20 0.43
▸ HPGD P15428 2/20 0.43
▸ HSD17B10 Q99714 2/20 0.43
▸ GLA P06280 1/20 0.43
▸ CYP3A4 P08684 1/20 0.43
▸ SMN1; SMN2 Q16637 1/20 0.43
▸ ALOX15 P16050 2/20 0.38
▸ RAB9A P51151 2/20 0.38
▸ PPARG P37231 2/20 0.38
▸ HDAC6 Q9UBN7 1/20 0.38
▸ PTPN1 P18031 1/20 0.38
▸ HTT P42858 1/20 0.38
▸ MEN1 O00255 2/20 0.38
▸ KMT2A Q03164 2/20 0.38
▸ POLB P06746 1/20 0.38
▸ ALOX12 P18054 1/20 0.38
▸ KLK7 P49862 1/20 0.38
▸ KCNA3 P22001 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5273069 0.86 PTPN1 (0.48) KDM4EHSD17B10ALOX15RAB9APPARG
SCHEMBL5270960 0.84 ALDH2 (0.52) ALOX15RAB9AALOX12KLK7ALDH2
SCHEMBL5269467 0.83 PPARG (0.46) SMN1; SMN2PPARGMEN1KMT2AMAPT
SCHEMBL5271921 0.81 ALDH2 (0.53) ALOX15RAB9AALOX12KLK7ALDH2
SCHEMBL5267899 0.81 ALDH2 (0.46) PPARGALDH2MAOAMAOB
SCHEMBL234246 0.79 KDM4E (0.67) ALDH1A1KDM4EUSP2HPGDHSD17B10
SCHEMBL234545 0.76 ALOX12 (0.51) ALDH1A1KDM4EUSP2HPGDHSD17B10
SCHEMBL5266878 0.73 ALOX12 (0.48) ALDH1A1KDM4EUSP2HPGDHSD17B10
SCHEMBL5271608 0.73 ALOX12 (0.48) ALDH1A1KDM4EUSP2HPGDHSD17B10
SCHEMBL14396124 0.73 KDM4E (0.65) ALDH1A1KDM4EUSP2HPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1456180-B1 3-(2,4)DIHYDROXYPHENYL-4-PHENYLPYRAZOLES AND THEIR MEDICAL USE VERNALIS CAMBRIDGE LTD (GB) 2007-10-03 — — EP disclosed
EP-1456180-B1 3-(2,4)DIHYDROXYPHENYL-4-PHENYLPYRAZOLES AND THEIR MEDICAL USE VERNALIS CAMBRIDGE LTD (GB) 2007-10-03 — — EP disclosed
US-7247734-B2 3,4-diarylpyrazoles and their use in the therapy of cancer VERNALIS (CAMBRIDGE) LIMITED (GB) 2007-07-24 — — US disclosed
US-7247734-B2 3,4-diarylpyrazoles and their use in the therapy of cancer VERNALIS (CAMBRIDGE) LIMITED (GB) 2007-07-24 — — US disclosed
US-20050222230-A1 3,4-diarylpyrazoles and their use in the therapy of cancer VERNALIS (CAMBRIDGE) LIMITED (GB) 2005-10-06 — — US disclosed
EP-1456180-A1 3,4-DIARYLPYRAZOLES AND THEIR USE IN THE THERAPY OF CANCER Vernalis (Oxford) Ltd (GB) 2004-09-15 — — EP disclosed
WO-2003055860-A1 3,4-DIARYLPYRAZOLES AND THEIR USE IN THE THERAPY OF CANCER VERNALIS (CAMBRIDGE) LIMITED (GB) 2003-07-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050222230-A1 3,4-diarylpyrazoles and their use in the therapy of cancer HSP90AB1, HSP90AA1, HSP90AB2P ALDH1A1 986/4885KDM4E 1999/4885USP2 2347/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback